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A recent meta-analysis suggested that Hypericum
perforatum (St John’s wort) is an effective
treatment for mild to moderate depression and
may have a superior side-effect profile to some
antidepressant drugs. The aim of this study was to
assess the use of herbal remedies in treating
depressive and anxiety symptoms, as reported by
members of the UK self-help organization
Depression Alliance using self-completed
questionnaires. More than 50% of the 452
respondents reported using Hypericum, one-
quarter of whom also reported concurrent use of
traditional antidepressants. Most of the sample
reported sufficient symptoms for warranting a
diagnosis of major depression, with the majority
also describing symptoms suggestive of co-morbid
psychiatric conditions. One-half of the Hypericum
users experienced symptom improvement, which
for most occurred within the first 4 weeks of use.
Response was better for those with mild as
compared to severe symptoms and poorer for
those taking Hypericum alongside other
antidepressants. The responders were generally
older than non-responders. Adverse effects were
reported by one-quarter of users and were mostly
psychological in nature. This retrospective survey
indicated that use of herbal remedies was
common in this population. Although often helpful
in relieving symptoms, particularly in those with
mild depression, there is a risk of adverse events
and drug interactions.
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Introduction
Depressive disorders are a significant
cause of morbidity. The lifetime preva-
lence of major depressive disorder is
approximately 20% for women and is
approximately half that for men.1
Antidepressants are the most common
treatment, although psychological 
interventions such as cognitive–
behavioural therapy and (rarely) electro-
convulsive therapy are also an option.
Antidepressants are an effective treat-
ment in moderate to severe depression
with approximately 70% of patients
responding within 3 months.1
Unfortunately side-effects are also com-
mon, which can reduce compliance and
life quality. Consequently, an effective
agent with fewer side-effects than con-
ventional drugs would be beneficial for
patients, particularly those with milder
symptoms.
Hypericum has been used as a
herbal remedy for centuries for its
wound-healing, anti-viral, anti-inflam-
matory, sedative and antidepressant
properties. However, recent interest
has focused primarily on its use as an
antidepressant. The use of Hypericum
is increasing, along with other compli-
mentary and alternative medicines.2,3 A
recent UK population study reported a
lifetime use of 46.6% for complimenta-
ry approaches,4 although individuals
over the age of 65 years were found to
be less likely to use such remedies and
women were more likely to use them
than men.4
Hypericum has a complex pharma-
cology, mimicking the effects of many
classes of antidepressants5 including
the inhibition of reuptake of serotonin
(5-HT), noradrenaline, dopamine,
GABA (g-aminobutyric acid) and gluta-
mate. Hypericum also appears to be an
inhibitor of cytokine expression, in
particular IL-6 (interleukin-6), which
may be over-expressed in depression.5
Studies have shown Hypericum to be
an effective treatment for depression
with approximately 60–70% of patients
responding to treatment,6,7 particularly
in mild depression. Linde et al.6 con-
cluded that Hypericum extract was sig-
nificantly more effective than placebo
and similarly effective to conventional
antidepressants. However, in a recent
study Hypericum was found to be no
more efficacious than placebo in mod-
erate to severe or severe depression.8
This may have been due to the poor
assay sensitivity of that study as sertra-
line also failed to differentiate from
placebo. In addition, many treatment
studies have been criticized for using
low doses of conventional medication
and for inconsistent classification of
depressive disorders. Further data are
required regarding Hypericum use in
different patient populations, such as
those with severe depression or those
with symptoms not fulfilling the criteria
for major depression.
A number of side-effects have been
noted with Hypericum, although serious
adverse events may be relatively rare
compared to the rates of usage.
Nevertheless, studies have shown inter-
actions between Hypericum and con-
ventional antidepressants.9,10 Hypericum
may be superior to conventional med-
ications in its incidence of side-effects or
adverse drug reactions.11 One meta-
analysis6 found side-effects in 19.8% of
cases, while a systematic review12
reported a range of 12–38%. The side-
effects of Hypericum are generally mild
to moderate in intensity and include
temporary gastrointestinal disturbance,
restlessness, dizziness, fatigue and a dry
mouth.7,12,13 Allergic reactions are rare
and photosensitivity is very rare at ther-
apeutic doses.12 However, the lack of
data on long-term safety and the possi-
bility of drug interactions mean that
Hypericum should be used with care.
Most trials assessing the efficacy of
Hypericum have been conducted on
restricted subsets of patients, usually
with diagnoses of major depressive dis-
order. However, there are many individ-
uals who do not fulfil the diagnostic cri-
teria for this disorder, but who still
experience significant distress and are
likely to use Hypericum for relieving
their symptoms. Consequently, the par-
ticipants in this study were recruited
from among the membership of the UK
self-help organization Depression
Alliance. The first part of the investiga-
tion was a retrospective study using
questionnaires for investigating the use
of herbal remedies for depressive and
anxiety symptoms. It was predicted that
the reported treatment response to
Hypericum would decrease with
increased depression severity and
greater duration of symptoms. It was
also expected that the reported
response would be poorer in those tak-
ing other antidepressants alongside
Hypericum and for those who reported
co-morbid psychiatric conditions. A fur-
ther aim of the study was to examine
the effect of age and gender on the
Hypericum treatment response. This has
received little attention in the literature.
The second part, a prospective study
using the Hospital Anxiety and
Depression Scale and Clinical Global
Improvement Scale, is currently being
conducted and aims to indicate the
effectiveness and tolerability of a
Hypericum preparation in a study
group that is possibly more representa-
tive of Hypericum users.
Methods
Participants
The sample consisted of 452 volunteers
who were recruited from the member-
ship of Depression Alliance (UK). The
mean age of the respondents was 46.9
years and 72.7% were women.
Southampton and South West Hants
Local Research Ethics Committee
(S39/00) granted ethical approval in
accordance with the principles of the
Declaration of Helsinki.
Materials
A questionnaire designed by one of the
authors (R.D.) was used for obtaining
information from the participants
regarding their previous and current
use of herbal remedies, the duration
and severity of their depressive symp-
toms, the extent of co-morbid condi-
tions and their responses to Hypericum
along with side-effects and adverse
events associated with Hypericum use.
Procedure
Questionnaires were sent by post to
the complete membership (n = 2700)
of Depression Alliance from whom 452
completed forms were received. These
were completed by the participants
and returned to the researchers.
Confidentiality was assured.
Results
Since the participants were all mem-
bers of Depression Alliance, they all
considered themselves to be
depressed, although there was no
guarantee how many of them had
received a formal psychiatric diagnosis.
Their mean symptom duration was
13.9 years.
Three hundred and sixty-five
(80.8%) of the 452 respondents were
currently taking medication and 227
(50.2%) were taking a traditional anti-
depressant. Ninety-two (40.5%) partici-
pants reported taking selective sero-
tonin reuptake inhibitors, 55 (24.2%)
were taking tricyclic antidepressants
and 80 (35.3%) participants reported
taking ‘other’ antidepressants. Overall
302 participants (66.8%) reported tak-
ing some form of herbal remedy, 229
(75.8%) of whom reported taking
Hypericum. Sixty-six participants
(28.8%) reported combining
Hypericum and an antidepressant.
Overall 191 (63.2%) of those taking
herbal remedies such as Hypericum
said that they used the preparation for
‘depression’, while 42 (13.9%) men-
tioned depression/anxiety and 25
(8.3%) stated that they used Hypericum
for anxiety alone. Little effect was
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found for age with respect to
Hypericum use, but those over 65
years of age were significantly less like-
ly to use Hypericum than those under
65 years (χ2 = 4.096 and P < 0.05).
There was no effect of gender.
Two hundred and seventy-seven
(91.7%) of the 302 herbal remedy users
experienced symptoms that might
receive a DSM-IV (Diagnostic and
Statistical Manual of Mental Disorders,
fourth edition) diagnosis of major
depressive disorder. Most of the
respondents (252) also reported co-
morbid problems or conditions along-
side depression (83.4%), 207 (68.5%)
of whom reported anxiety/panic disor-
der, 61 (20.2%) an eating disorder and
35 (11.6%) substance abuse. Only 240
participants reported the degree of
their depression severity: 44 partici-
pants (18.3%) reported ‘mild’ symp-
toms, 119 (49.6%) reported ‘moderate’
symptoms and 77 (32.1%) reported
‘severe’ symptoms.
Of the respondents describing the
effect of Hypericum on their symp-
toms, 119 (51.9%) experienced
improvement, 92 (40.2%) described
their symptoms as unchanged and 18
(7.9%) described a worsening of their
symptoms. Of those reporting improve-
ment, 91 participants (76.4%) reported
that this occurred within 4 weeks and
57 (47.9%) between 2 and 4 weeks.
The response was significantly better in
those participants with mild as com-
pared to severe symptoms (χ2 = 12.32
and P < 0.05). However, there was no
effect on response with respect to
symptom duration. Response was
poorer though for those taking
Hypericum with an antidepressant as
opposed to Hypericum alone (χ2 =
13.16 and P < 0.05). Symptom co-mor-
bidity had no effect on response to
treatment and there was no effect of
gender. In respect of age, the respon-
ders were generally older than non-
responders (mean age 49.3 versus 45.8
years) (P < 0.05).
Sixty-three participants (27.5% of
users) reported adverse effects of
Hypericum: of these 24 (10.4%) report-
ed psychological symptoms, ten (4.3%)
described headaches and dizziness,
nine (3.9%) mentioned allergic reac-
tions (itching, rashes), eight (3.5%)
referred to gastrointestinal problems,
seven (3.1%) reported general aches
and pains and five (2.1%) reported
visual disturbances. These side-effects
remitted within 1 week for 31 partici-
pants (50%) and within 1 month for 50
of them (79.5%).
Discussion
The use of herbal remedies was com-
mon in this sample and at 66.8% is
much higher than the UK average use
of these remedies (31.4%).4 Members
of a self-help organization may be pre-
cisely the kind of individuals who are
more likely to use complimentary
approaches than those in more tradi-
tional settings. Hypericum was consid-
erably more popular than other types
of remedy reported by these partici-
pants, which may reflect the consider-
able media attention that this com-
pound currently receives.
The overall response rate to
Hypericum of 51.9% by users, while of
a similar magnitude, was marginally
lower than those rates previously
reported (60–70%).6,7 This may reflect
the inclusion here of participants who
would be excluded from randomized
controlled trials, for example due to
severe or chronic depression or use of
antidepressant medication. As predict-
ed, response was significantly better
for those with milder as compared to
more severe symptoms. This supports
findings in the literature that
Hypericum treatment is effective in
those with mild–moderate disease but
less so in severe disease.6–8 However,
the expected effect for symptom dura-
tion against the response rate was not
found. As predicted, response was
poorer for those taking Hypericum
alongside a traditional antidepressant
as compared to those taking the med-
ication alone. However, against expec-
tations there was no effect for symp-
tom co-morbidity on the response
rates. These issues warrant further
research since little has been reported
about this relationship.
The study revealed an age-related
effect on both the use of herbal reme-
dies and response to Hypericum treat-
ment. Those over 65 years were less
likely to use herbal remedies. This find-
ing was supported by a recent study,
which also found lower rates of com-
plementary and alternative medicine
(CAM) use in the over 65 years age
group.4 In respect to response rates
and age, the current study found that
the responders were significantly older
than non-responders. Research has
found that women have a significantly
higher use of herbal remedies,4 but this
was not replicated here. This may be
because gender did not affect use in
the current study population or it could
have been due to the low percentage
of male respondents. Furthermore, the
current study found no effect of gender
on treatment response. Again, further
research is warranted in this respect.
A key finding in the current study
was that 7.9% of Hypericum users
described a worsening of symptoms
and 27.5% experienced one or more
adverse events and, thus, Hypericum
treatment is not without potential
drawbacks. A recent meta-analysis6
quoted a 19.8% incidence of side-
effects and a systematic review12 found
incidences ranging from 12 to 38%. The
incidence here was similar to these fig-
ures, as was the nature of the side-
effects, although more studies could be
conducted on psychological distur-
bances associated with use.
Nevertheless, the level of adverse
effects remains a cause for concern,
particularly as more participants
obtained information on taking
Hypericum from the media than they
did from health professionals. This is
disturbing for two reasons: Hypericum
users may not be receiving adequate
information on the safety of using the
preparation and general practitioners
may be unaware that their patients are
taking Hypericum when they prescribe
other treatments. This was compound-
ed by the finding here that 28.8% of the
Hypericum users also took a tradition-
al antidepressant, thereby risking drug
interactions such as serotonin syn-
drome.9 While this is unlikely, a possi-
ble case has been reported in the liter-
ature.10
Summary and
implications
These results suggest that patients with
mild or a low number of symptoms
may respond well to Hypericum irre-
spective of symptom duration. Thus,
Hypericum may be a reasonable alter-
native to conventional antidepressants
in these patients, particularly if they
experience troublesome side-effects
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with these medications. Due to the
high number of people taking herbal
remedies and the risk of associated
adverse events or drug interactions, it
is important that doctors are fully
aware of what preparations their
patients are taking.
Further studies are required in order
to examine the reliability and validity of
the measures used here. Furthermore,
whilst the application of self-completed
questionnaires is an efficient method of
data collection, little information was
available on formal diagnoses or on the
dosage of Hypericum taken.
Nevertheless, useful preliminary infor-
mation for assessing the merit of
Hypericum in people with mild to mod-
erate depression is presented in the
data provided by this study.
Collaborating
organizations
Depression Alliance is the UK’s leading
charity working for people affected by
depression. It coordinates self-help
groups, provides support and informa-
tion, campaigns in order to raise aware-
ness and conducts research into the
incidence, experience and treatment of
depression. The organization has 20
full-time staff and 2700 members.
The St John’s Wort Information
Centre is an independent organization
providing information and advice about
Hypericum and conducting research
into its use, efficacy and tolerability.
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